SGLT-2 Inhibitor Jardiance Helps Those Living with Heart Failure
Jardiance (empagliflozin), an SGLT-2 inhibitor, was recently approved by the FDA to help adults who have heart failure with reduced ejection fraction (HFrEF). Results from EMPEROR-Preserved also show Jardiance benefits those with heart failure with preserved ejection fraction (HFpEF).
Heart failure, one of the most common diabetes-related complications, affects over six million Americans and leads to about a million hospitalizations each year. People with type 2 diabetes diabetes are two to four times more likely to develop heart failure.
Heart failure occurs when the heart isn’t able to pump enough blood to the rest of the body. One type of heart failure is associated with reduced ejection fraction, or HFrEF. This type occurs when the heart muscle becomes weak and is unable to pump enough blood through the body with each heartbeat. HFrEF occurs when the percentage of blood released to the body is less than half of the amount in the heart chamber. Heart failure with preserved ejection fraction (HFpEF) on the other hand is caused by the heart muscle becoming too stiff, however in this type, the heart is still able to pump more than half of the blood in the chambers out to the rest of the body.
There are a small number of treatment options for people experiencing heart failure, including SGLT-2 inhibitors, which are primarily medications used to lower blood glucose levels. One of these drugs, Jardiance (empagliflozin), was recently approved by the FDA to treat heart failure with reduced ejection fraction (HFrEF) in people with and without diabetes.
Based on results from the EMPEROR-Reduced trial, Jardiance is approved to reduce the risk of cardiovascular death and hospitalization for heart failure if you have HFrEF. The trial, which included 3,730 people, both with and without type 2 diabetes, showed that Jardiance reduced the risk of heart failure by 25% compared to those receiving a placebo. The trial also showed that Jardiance reduced the risk of first and recurrent hospitalization for heart failure by 30% compared to the placebo.
"Heart failure is a chronic, debilitating cardio-renal-metabolic condition affecting over 60 million people worldwide,” said Dr. Javed Butler, chairman of the Department of Medicine, University of Mississippi, in a statement from Lilly on the approval earlier this month. "As the prevalence of heart failure continues to rise, the need for new treatment options is critical. Empagliflozin is a vital new therapeutic option to reduce the risk of cardiovascular death and hospitalization for adults with heart failure with reduced ejection fraction."
Jardiance is now the second SGLT-2 inhibitor to have been shown and approved to treat this condition, following Farxiga (dapagliflozin) in 2020.
In other exciting news, Jardiance has also been shown to be the first drug to show significant benefits for people with heart failure with preserved ejection fraction (HFpEF) – though it has not received an official FDA approval for this yet. In results published in the New England Journal of Medicine from the EMPEROR-Preserved trial which included 5,988 study participants, Jardiance was shown to reduce the risk of risk of cardiovascular death and hospitalization for HFpEF by 21% compared to those receiving a placebo. The trial also showed that Jardiance reduced the risk of first and recurrent hospitalization for heart failure by 27% compared to the placebo and significantly slowed kidney decline.
Jardiance is the first and only SGLT-2 inhibitor drug to have data showing its benefits for the full population of patients with established heart failure (regardless of type).
To learn more about heart failure – what it is, its relation to diabetes, and your treatment and prevention options – you can check out our two-part series on the subject.